Latest Content

Novartis and Bristol Myers Squibb pause autoimmune CAR-T trials over safety concerns, a dealmaking roundup covers Alteogen's licensing deal with Novartis, NewBiologix's gene therapy partnership with Synastra, and RedHill's acquisition of Rebyota and Clenpiq from Ferring, and Lexi Cogswell and Tom Rotolo make the case for real-world insights in obesity medical strategy.

Novartis suspends eight autoimmune trials of its CAR-T therapy Rap-cel after three cases of fatal outcomes, while Bristol Myers Squibb voluntarily pauses enrollment in its Zola-cel autoimmune studies over transient inflammatory events.

Alteogen grants Novartis options to develop subcutaneous formulations using its ALT-B4 hyaluronidase platform, NewBiologix and Synastra partner to develop a stable producer cell line, and RedHill acquires global commercialization rights to Ferring's Rebyota and Clenpiq.

Real-world evidence tells you what happened. Real-World iNSIGHTS tell you why — and what to do next. A new framework for medical affairs.

Nate Hill, co-founder & CEO, Strive, explains how Strive is managing peptide uncertainty by pre-sourcing API, running stability and testing, and working with legal counsel to calibrate risk.

Carelon Research's Mark Cziraky on why bringing compute to data — not moving data — reduces risk and accelerates real-world evidence generation.

The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA flu vaccine into Phase III, and Simcere Zaiming licenses its tri-specific antibody Sim0660 to Roche for up to $1.53 billion.

A Harvard Business School Healthcare Alumni Association Q&A with Stuart B. Gleichenhaus, senior managing director at FTI Consulting, who has also served as an interim CEO/CFO of five healthcare companies.

Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 billion, including a $75 million upfront payment.

RBQM implementations fail not because the software is wrong — but because the human environment surrounding it was never engineered.

Nate Hill, co-founder & CEO of Strive Pharmacy, argues that a Category one designation for peptides would give physicians a trusted, regulated channel they currently lack.

ACTO’s CEO on AI trust, the future of the sales rep, and why human intelligence plus empathetic agents is the winning formula.

Carelon Research's Mark Cziraky on why the industry's need for deeper, linked data is driving a shift toward trusted research environments.